Abstract

BackgroundHuman immunodeficiency virus type 1 (HIV-1) has evolved a complex strategy to overcome the immune barriers it encounters throughout an organism thanks to its viral infectivity factor (Vif), a key protein for HIV-1 infectivity and in vivo pathogenesis. Vif interacts with and promotes “apolipoprotein B mRNA-editing enzyme-catalytic, polypeptide-like 3G” (A3G) ubiquitination and subsequent degradation by the proteasome, thus eluding A3G restriction activity against HIV-1.ResultsWe found that cellular histone deacetylase 6 (HDAC6) directly interacts with A3G through its C-terminal BUZ domain (residues 841–1,215) to undergo a cellular co-distribution along microtubules and cytoplasm. The HDAC6/A3G complex occurs in the absence or presence of Vif, competes for Vif-mediated A3G degradation, and accounts for A3G steady-state expression level. In fact, HDAC6 directly interacts with and promotes Vif autophagic clearance, thanks to its C-terminal BUZ domain, a process requiring the deacetylase activity of HDAC6. HDAC6 degrades Vif without affecting the core binding factor β (CBF-β), a Vif-associated partner reported to be key for Vif- mediated A3G degradation. Thus HDAC6 antagonizes the proviral activity of Vif/CBF-β-associated complex by targeting Vif and stabilizing A3G. Finally, in cells producing virions, we observed a clear-cut correlation between the ability of HDAC6 to degrade Vif and to restore A3G expression, suggesting that HDAC6 controls the amount of Vif incorporated into nascent virions and the ability of HIV-1 particles of being infectious. This effect seems independent on the presence of A3G inside virions and on viral tropism.ConclusionsOur study identifies for the first time a new cellular complex, HDAC6/A3G, involved in the autophagic degradation of Vif, and suggests that HDAC6 represents a new antiviral factor capable of controlling HIV-1 infectiveness by counteracting Vif and its functions.Electronic supplementary materialThe online version of this article (doi:10.1186/s12977-015-0181-5) contains supplementary material, which is available to authorized users.

Highlights

  • Human immunodeficiency virus type 1 (HIV-1) has evolved a complex strategy to overcome the immune barriers it encounters throughout an organism thanks to its viral infectivity factor (Vif ), a key protein for human immunodeficiency virus (HIV)-1 infectivity and in vivo pathogenesis

  • Quantitation of western blots regarding HA-histone deacetylase 6 (HDAC6)- and EGFP-HDAC6-ΔBUZ-mediated Vif degradation. b, c Cell lysates from control scrambled (SCR) or small interfering RNA (siRNA)-HDAC6-treated cells, expressing recombinant or proviral Vif

  • Our results show for the first time that HDAC6, through its C-terminal bound to ubiquitin zinc finger (BUZ) domain, induces the degradation of Vif without affecting core binding factor β (CBF-β) and protects A3G from its Vif-induced degradation

Read more

Summary

Introduction

Human immunodeficiency virus type 1 (HIV-1) has evolved a complex strategy to overcome the immune barriers it encounters throughout an organism thanks to its viral infectivity factor (Vif ), a key protein for HIV-1 infectivity and in vivo pathogenesis. APOBEC3G (apolipoprotein B mRNA-editing enzymecatalytic, polypeptide-like 3G or A3G) is a member of the APOBEC superfamily of cytidine deaminases [1], which are thought to restrict human immunodeficiency virus type 1 (HIV-1) activity. A3G might, diversify the viral genome, thereby promoting infectious HIV-1 variants and even generating HIV-1 drug-resistant phenotypes [21,22,23,24]. These data suggest the existence of a complex A3G-mediated restrictive function against HIV-1, potentially dependent on a variety of A3G targets [12, 25, 26]

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.